Reaction

Lymphocyte Count Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,225 reports · 81 co-occurring drugs

As of the last recalculation, Lymphocyte Count Increased appears in 3,225 FAERS reports alongside 81 co-occurring drug terms. The strongest observed disproportionality signal is CLOZAPINE (PRR 25.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Clozapine	435	25.7	25.8
Ibrutinib	259	22.4	22.5
Obinutuzumab	50	19.9	20.0
Valproate Sodium	43	13.6	13.6
Acalabrutinib	23	12.3	12.4
Fingolimod Hcl	148	11.5	11.5
Venetoclax	96	10.3	10.4
Dexamethasone Sodium Phosphate	16	10.2	10.2
Cholestyramine	18	9.7	9.7
Ribociclib	46	9.5	9.5
Trimethoprim	16	8.8	8.8
Cefuroxime	15	8.5	8.5
Losartan Potassium And Hydrochlorothiazide	14	7.8	7.8
Haloperidol	25	6.7	6.7
Abacavir Sulfate	10	6.6	6.6
Methimazole	8	6.6	6.6
Haloperidol Lactate	25	6.6	6.6
Tofacitinib Citrate	13	6.4	6.4
Anti-Thymocyte Globulin (Rabbit)	8	6.4	6.4
Alemtuzumab	19	6.4	6.4
Nilotinib	27	6.0	6.0
Infliximab-Dyyb	26	5.8	5.8
Letrozole	54	5.7	5.7
Doxyclycline Hyclate	15	5.7	5.7
Glyburide	21	5.6	5.6
Letrozole Tablets	41	5.6	5.6
Niraparib	19	5.6	5.6
Dapsone	9	5.5	5.5
Bendamustine Hydrochloride	10	5.4	5.4
Deferasirox	22	5.4	5.4
Daspone	8	5.3	5.3
Dapsone Gel, 5%	8	5.3	5.3
Febuxostat Tablets 40 Mg	8	5.1	5.1
Febuxostat Tablets 80 Mg	8	5.1	5.1
Olanzapine	82	5.0	5.0
Blinatumomab	8	5.0	5.0
Olanzapine Pamoate	30	4.8	4.8
Gemfibrozil	11	4.7	4.7
Lithium	18	4.6	4.6
Lithium Bromatum	18	4.6	4.6
Tizanidine	17	4.6	4.6
Sulfasalazine	55	4.6	4.6
Ceftriaxone Sodium	26	4.4	4.4
Valproic Acid	21	4.3	4.3
Eltrombopag Olamine	15	4.2	4.2
Fulvestrant	21	4.1	4.1
Asfotase Alfa	6	3.9	3.9
Rifampicin	6	3.8	3.8
Natalizumab	103	3.7	3.7
Siponimod	5	3.6	3.6
Testosterone Cypionate	5	3.6	3.6
Ipilimumab	24	3.6	3.6
Voriconazole Injection	12	3.6	3.6
Tocilizumab	62	3.6	3.6
Febuxostat	9	3.5	3.5
Paliperidone	12	3.3	3.3
Entecavir	6	3.3	3.3
Aripiprazole	61	3.3	3.3
Diroximel Fumarate	6	3.3	3.3
Acetaminophen And Codeine	6	3.2	3.2
Ofatumumab	16	3.1	3.1
Iohexol	4	3.1	3.1
Naltrexone Hydrochloride And Bupropion Hydrochloride	4	3.0	3.0
Bimatoprost	13	2.9	2.9
Bosutinib	4	2.9	2.9
Dasatinib	16	2.8	2.8
Isotretinoin	21	2.8	2.8
Somatropin	28	2.5	2.5
Ixazomib	11	2.5	2.5
Palbociclib	36	2.5	2.5
Eculizumab	20	2.4	2.4
Ocrelizumab	22	2.3	2.3
Dalfampridine	25	2.3	2.3
Rucaparib	3	2.2	2.2
Ruxolitinib	24	2.2	2.2
Dimethyl Fumarate	41	2.2	2.2
Avapritinib	4	2.1	2.1
Cariprazine	3	2.1	2.1
Nivolumab	30	2.0	2.0
Certolizumab Pegol	36	2.0	2.0
Ravulizumab	4	1.9	1.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.